The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Tag Archives: Pfizer

Biotech Trends Update — Biosimilars Blur IP Constituencies: Novartis and Pfizer-Biocon are Featured in the Economist

Two 9-figure announcements this week mark a turning point for the biosimilars market, and one highlights the increasingly important role India plays in innovation. Pfizer linked up with India’s Biocon in a deal that will see Biocon take the lead in development of four biosimilar insulin products that gives Biocon $200 million up front. Coverage of [...]

Patent Cliff Will Not Save Biotech: Abbott Buys Indian Generics Company Piramal Healthcare

I often hear how the upcoming loss of patent protection for current blockbusters creates an insatiable demand at pharma companies for new pipeline products from biotechs. Here’s an example from 2007. Here’s one from last week. This is not true. Upcoming loss of patent protection creates a insatiable demand for revenue, but new products are not [...]

Monday Biotech Deal Review: March 22, 2010

Bought deals are all the rage this week, with BioExx and Osta Biotechnologies both heading in that direction.  Also, everywhere we look, warrants are being exercised and debentures are being converted. We even noted the green shoots of a new Canadian listed biotech company poking through the ground via a CPC transaction.  Is there a [...]

Biotech Trends Update — IP Constituencies: Innovators and Generics Continue to Blur Pharma Lines

Two stories noted by the WSJ’s Health Blog highlight the trend we’ve been following of blurring lines between branded/innovator pharma and generics companies: The biggest development I’d cite is Pfizer’s deal to sell 40 generics made by India’s Strides Arcolab and South Africa’s Aspen.  This deal seems to go a step farther than other innovator/branded deals with [...]

Monday Biotech Deal Review: December 21, 2009

This week’s deal review shows no signs of a holiday showdown.  In Canada, BioMS’ deal with Spectral Diagnostics was interesting as a possible indicator of more to come and internationally, 5 new pharma deals were announced this morning including a $430 million deal that OncoGenex landed from Teva joining new links between Athersys and Pfizer, Lilly and Incyte, sanofi-aventis [...]

Novel Deal Structures Becoming More Common

At the RIC/OCETA talk I participated in last month, one of the trends in deal-making that I mentioned was novel structures.  At the time, examples included option deals and new ways to split rights and territories.  More recently, we’ve seen GSK and Pfizer form a joint venture to develop HIV treatments, and two more interesting ideas [...]

IVB’s Great Take on the GSK-Pfizer HIV Joint Venture

The In Vivo Blog has a really interesting post by Roger Longman discussing what they view as the groundbreaking and innovative aspects of GSK and Pfizer’s HIV joint venture, announced just over a month ago.  The gist is: The venture allows flexibility and accountability in an R&D operation with pharma-scale resources; and The JV has its [...]

BIO 2009: Ontario Premier’s Breakfast

The speeches (s-peach-es?) just finished this morning at the Ontario Premier’s breakfast. Minister of Research and Innovation John Wilkinson announced that Ontario has recently completed 2 new BIP investments: a Pfizer collaboration with the Ontario Institute for Cancer Research (OICR); and GSK Canada for manufacturing in Mississauga. Ontario’s Premier — Dalton McGuinty, winner of BIO’s [...]

Wednesday Brain Dump: Two of Everything! Edition

Two Camels!  Dolly the cloned sheep, meet Injaz the cloned camel. Two R&D Heads!  The combined Pfizer-Wyeth will have Mikael Dolsten heading up the newly created BioTherapeutics Research Group and Martin Mackay heading up the small molecule PharmaTherapeutics Research Group.  (Two CapitalLetters!)  The In Vivo Blog has a podcast interviewing both. Two VA Initiatives!  In addition to the electronic [...]

Wednesday Brain Dump: Deal-O-Rama Edition

There’s still plenty of deal activity in the pharma and biotech sector this week, even outside Canada, so here’s a roundup of what’s done, what’s pending and what’s in the rumor mill:

Trends Update: ChinaBio and Shantha Biotech

One of our Trends in 2009 posts last week talked about the increasing innovative activity in India and China and increasing generics activity among innovator pharma.  This week starts with a relevant update on each front: A report from Seeking Alpha on the ChinaBio Investor Forum that was recently held in Hong Kong, noting domestic companies GeneHarbor [...]

Wednesday Brain Dump: Around the World Edition

Click on the map points for each story, or just read on

Trends in 2009: Shifting IP Constituencies as Innovator Pharma Buys Generics and Asia Turns to Innovation

Growing industrial and geopolitical realignment of economic interests has the potential to re-define intellectual property constituencies in 2009. 1.  Industrial realignment: the entry of innovator pharma companies into the generics business. This year has already seen Merck get into follow-on biologics by buying Insimed and Pfizer build its generics business with its Aurobindo deal.  As traditional innovator pharma [...]

Wednesday Brain Dump: February 25, 2009

The question this week: a shot in the arm or a kick in the teeth? A shot in the arm for: Fewer shots in the arm! (har)  British Columbia is the first jurisdiction in North America to offer a children’s vaccine called Infanrix-hexa™, which contains six immunizations in one, resulting in three fewer needles in [...]

Personalized Medicine: The “SNP Doctor”

BIO SmartBrief picked up a story today about a device being tested called the mohel Snip Doctor, a hand-held diagnostic device that: looks for known single nucleotide polymorphisms (SNPs) – single letter changes in the genetic code – that can affect an individual’s response to medical treatment. While most current approaches to personalized medicine are mechanistic (e.g., [...]

It’s Raining M&A: Update

Canadian developments first: MDS (TSX:MDS; NYSE:MDZ) announced that it’s forming a special committee to “support the Company’s continuing process of reviewing alternatives to improve shareholder value.”  According to the press release: The committee is comprised of William Anderson, Robert Luba, James MacDonald and Gregory Spivy, each of whom is independent of management. James MacDonald will [...]

It’s Raining M&A

Pfizer-Wyeth is certainly the biggest headline (see here for info on those companies in Canada), but it seems like a very popular time to be shopping.

Pfizer-Wyeth in Canada

Following today’s developments, some Canadian stats from the Pfizer Canada and Wyeth Canada web sites:

Follow

Get every new post delivered to your Inbox.

Join 93 other followers